Single anti-undrant Lizhu Group spin-off reagent plate listed to see is 80 billion market mouth?

Pharmaceutical network August 12th, had high hopes of lizhu single anti-split listing plan has not yet landed, Lizhu Group wants to break up Lizhu reagent listing.
Lizhu Group announced on the evening of the 9th that it will spin off its controlling subsidiary Zhuhai Lizhu Reagent Co., Ltd. to list on the A-share market, in order to use the capital market to accelerate the company's development in diagnostic reagents and equipment.
If Lizhu reagents successfully listed, then the A-share market will appear the phenomenon of three generations of ancestral companies listed together, namely, Health Yuan Holding Lizhu Group, Lizhu Group Holding Lizhu Reagents.
01 single resistance has not landed, reagent plate first? Spin-off listing is an important means to optimize the allocation of resources in the capital market, not only will not affect the development of other sections, subsidiaries can also expand financing channels, achieve independent development and operation, in order to better promote the development of the Group, but also enhance the brand value and market influence of enterprises, especially at this stage of pharmaceutical enterprises generally high valuation nodes.
In December 2019, the CSRC officially issued the "Pilot Provisions for the Domestic Listing of Subsidiaries of Listed Companies" (hereinafter referred to as the "Split Rules"), which provides policy support for A-share companies to spin off subsidiaries into domestic listings, and listed companies will have more opportunities to spin off and list directly in the Mainland without changing their control.
first half of this year, there has been a wave of spin-offs of listed pharmaceutical companies.
A-share biopharmaceutical sector already has Hualan Bio, Colum Pharmaceuticals, Tian Shili, Changchun High-tech, Liaoning Chengda, Huabang Health, Yan'an Bikang announced a spin-off listing.
announcement, the spin-off is conducive to further enhance the brand awareness and social impact of Lizhu reagents, optimize the management and management system of Lizhu reagents, improve the management level of Lizhu reagents.
This spin-off and successful listing is conducive to Lizhu reagents to expand financing channels, further increase research and development, operational investment, thereby consolidating the market competitiveness of Lizhu preparations, and thus enhance Lizhu Group in the diagnostic reagents business sector bigger and stronger.
first half of this year, the company reported a net profit of 960 million yuan to 1.034 billion yuan, up about 30% to 40% year-on-year.
, the gains were mainly due to the sale of antiviral particles, testing reagents and the sale of pharmaceutical subsidiaries.
but for the current Lizhu Group, new earnings growth points are needed to boost confidence.
July 31 this year, Fujian Medical Insurance Bureau issued the Notice on the Publication of the First Batch of Health Insurance Focused Monitoring Drugs and Focusing on Drug Lists (hereinafter referred to as "Notices").
lizhu group's heavy-weight drug "injection with acetate bright propylene rhine micro-ball" is listed as "key monitoring" list.
according to the notification requirements, this also means that once the product is shipped in the month more than 5 million yuan, will be tasked with the production enterprises to lower the price, and the provincial drug joint procurement platform marked "yellow" logo.
if there is an anomaly, they will be alerted or removed from the health insurance directory;
the drug was developed by Shanghai Lizhu Pharmaceutical Co., Ltd., a subsidiary of the Group, to promote the name "Bay", specializing in the treatment of female diseases.
the same domestic products.
is currently only Japan's Takeda's original research drug to suppress Natong, has been achieved on the market.
in the new drug, Lizhu Group is still slow to commercialize.
its highly-expected single-resistance subsidiary has not been developing well this year.
its single-resistance company was established in 2010 by Fu Daotian, former vice president of the Group, and is also the general manager, responsible for the positioning of drug development, the formation of research teams, drug testing and reporting of the overall work.
2019, with an overseas background, Dai Weiguo, who worked in Johnson and Johnson's research and development department, became vice president of the group, took over the position of general manager of Single Resistance Company, and made extensive adjustments to the internal management team.
May 29 this year, Lizhu Group announced that Vice President Dai Weiguo, due to personal family and development reasons, resigned from all positions, responsible for drug research and development work, focusing on mono-anti-biotechnology.
's departure makes the development of its biopharmaceline sector even more difficult.
, neither Fu Daotian nor Dai Weiguo has been able to substantially promote the commercialization of biopharmaceers.
, Lizhu Group expected a separate spin-off of its single-anti-subsidiary.
2018, Lizhu Group announced that Yunfeng Fund will contribute US$50 million to subscribe for 12.5 million A-turn preferred shares issued by Lizhu Single Anti-Trump.
the two sides also announced that the Lizhu Group to "do its reasonable best" and strive to achieve the Lizhu single-resistance single listing by the end of 2022.
, the field of single resistance has become a domestic and foreign pharmaceutical enterprises competing for the layout of the "gold" industry.
some of the most popular target research and development pile serious, the competition is white hot.
's 2019 annual report shows that Lizhu Group biopharmace products a total of 9 projects in research, of which the focus of research and development of 3, are still in clinical trials, and with the track of The Real Biology, Baiji Shenzhou, etc., has been approved for listing, in a leading position.
02 Bet diagnostic reagents, generating $1 billion in revenue or peace of mind is clear, Lizhu Group wants the reagent companies that are above the wind to get back in the game.
since 2018, the number of investment and financing projects in this area of in-body diagnostics has been increasing.
, especially in this outbreak, has further ignited the field of in-body diagnosis.
, one of the giants of in-body diagnostics, has seen rapid growth in revenue in recent years, with operating income rising from 1,319 million yuan in 2015 to 2.8 billion yuan in 2019, with an average annual compound growth rate of 20.71 percent.
This year, under the influence of the global demand for test kits for the new crown outbreak, Huada Gene's first-quarter operating income was RMB791 million, an increase of 35.78 percent YoY, while the net profit attributable to shareholders of listed companies was RMB140 million, an increase of 42.59 percent YoY.
's first-quarter results rose at the same time, in the secondary market, Huada Gene's share price has risen nearly 60% so far this year.
, there is a lot of room in the in-body diagnostics industry.
according to the China Medical Device Industry Development Report (2017), China's in-body diagnostic market size in 2013 was 28.8 billion yuan, reaching 45 billion yuan in 2016, with an average annual compound growth rate of 16%.
expected that by 2020, China's in-body diagnostic reagents industry market size will exceed 80 billion yuan.
Institute of Forward-Looking Industries reports that there are only more than 60 products of in-body diagnostic reagents that have been industrialization in China, and are still weak in the fields of cancer, AIDS, cardiovascular disease and other products.
and the current global mature products have reached more than 1200 kinds, compared with foreign countries, China's diagnostic reagents market still has a larger blank market.
in the policy, China's new products each year to maintain a speed of more than 30% came out, the world's largest.
a new product is likely to bring hundreds of millions of market space, the pull effect on the industry is very obvious.
and Lizhu reagents are the only independent operating platform in the diagnostic reagents and equipment sector of Lizhu Group.
has been focusing on the development, production and sale of diagnostic reagents and equipment, and by the end of 2019, 14 products had received 15 medical device certificates in the European Union, 6 of which had passed TUV international certification on-site inspections.
the end of 2019, Lizhu reagent assets totaled 746 million yuan, owner's equity 190 million yuan.
2017-2019, Lizhu reagent revenue was RMB650 million, RMB710 million and RMB755 million, respectively, and net profit attributable to the owners of the parent company was RMB 780 million, RMB110 million and RMB105 million, respectively.
outbreak, Lizhu Reagent has developed several new coronavirus detection products in cooperation with the Wuhan Virus Research Institute of the Chinese Academy of Sciences.
the first new coronavirus IgG/IgM anti-medical test kit (collective gold method), which produces results in up to 15 minutes and was approved for sale in mid-March.
is expected to reach 45 million for the full year.
, which is expected to contribute more than 1 billion yuan in revenue to the Lizhu Group in 2020, is expected to be completed.
, however, as its announcement said, there are currently a large number of players in diagnostic reagents, Lizhu reagents have been listed in a number of diagnostic reagent products are facing the market of multiple manufacturers of direct competition or potential competition.
if the competition intensifies, if Lizhu reagents can not continue to maintain the advantage, then Lizhu Group may be more passive.
.